Article
Oncology
Omar Bohoudi, Anna M. E. Bruynzeel, Shyama Tetar, Ben J. Slotman, Miguel A. Palacios, Frank J. Lagerwaard
Summary: The study found that dose parameters based on total accumulated delivered bladder dose were better at predicting acute urinary symptoms. Additionally, dose parameters from the first 3 of 5 fractions also showed good correlation and could potentially be used to optimize MRgRT for the remaining fractions.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Karl Bordeau, Morgan Michalet, Aicha Keskes, Simon Valdenaire, Pierre Debuire, Marie Cantaloube, Morgane Cabaille, Fabienne Portales, Roxana Draghici, Marc Ychou, Eric Assenat, Thibault Mazard, Emmanuelle Samalin, Ludovic Gauthier, Pierre-Emmanuel Colombo, Sebastien Carrere, Francois-Regis Souche, Norbert Ailleres, Pascal Fenoglietto, David Azria, Olivier Riou
Summary: Stereotactic MR-guided Adaptive RadioTherapy (SMART) is a promising treatment for pancreatic tumors, providing effective and well-tolerated therapy. It has the potential to improve the management of pancreatic adenocarcinoma, but further studies are needed to confirm its exact role.
Article
Oncology
Darren M. C. Poon, Jing Yuan, Oi-Lei Wong, Bin Yang, Sin-Ting Chiu, Kin-Yin Cheung, George Chiu, Siu-Ki Yu
Summary: The study found that 1.5T MRgSBRT treatment for localized PC had low toxicity, supporting its clinical use.
Review
Oncology
John Michael Bryant, Joseph Weygand, Emily Keit, Ruben Cruz-Chamorro, Maria L. Sandoval, Ibrahim M. Oraiqat, Jacqueline Andreozzi, Gage Redler, Kujtim Latifi, Vladimir Feygelman, Stephen A. Rosenberg
Summary: Stereotactic body radiotherapy (SBRT) is an effective radiation therapy technique that shortens treatment courses by using daily image guidance. Magnetic resonance imaging (MRI) improves soft-tissue visualization for better tumor targeting. MR-guided SBRT (MRgSBRT) with a combined MRI and linear accelerator offers superior soft-tissue visualization, real-time assessment, and online adaptive replanning.
Article
Medicine, General & Internal
Karl Bordeau, Morgan Michalet, Aicha Keskes, Simon Valdenaire, Pierre Debuire, Marie Cantaloube, Morgane Cabaille, William Jacot, Roxana Draghici, Sylvain Demontoy, Xavier Quantin, Marc Ychou, Eric Assenat, Thibault Mazard, Ludovic Gauthier, Marie Dupuy, Boris Guiu, Celine Bourgier, Norbert Ailleres, Pascal Fenoglietto, David Azria, Olivier Riou
Summary: Liver stereotactic body radiotherapy (SBRT) provides effective local control and minimal toxicity for liver metastases. This study presents the first clinical results of stereotactic MR-guided radiotherapy (MRgRT) for liver metastases from a prospective registry. The treatment was well-tolerated, with low rates of acute and late toxicities. The overall survival and local control rates were promising, but distant relapse remains a challenge.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Karl Bordeau, Morgan Michalet, Valerie Dorion, Aicha Keskes, Simon Valdenaire, Pierre Debuire, Marie Cantaloube, Morgane Cabaille, Roxana Draghici, Marc Ychou, Eric Assenat, Marta Jarlier, Sophie Gourgou, Boris Guiu, Jose Ursic-Bedoya, Norbert Ailleres, Pascal Fenoglietto, David Azria, Olivier Riou
Summary: Magnetic Resonance guided Radiotherapy (MRgRT) for primary liver tumors is safe and achieves excellent local control without severe adverse events. This study observed no significant acute or late toxicities related to radiotherapy, and high overall survival and local control rates. Further research is ongoing in these areas.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Ting Martin Ma, James M. Lamb, Maria Casado, Xiaoyan Wang, T. Vincent Basehart, Yingli Yang, Daniel Low, Ke Sheng, Nzhde Agazaryan, Nicholas G. Nickols, Minsong Cao, Michael L. Steinberg, Amar U. Kishan
Summary: The MIRAGE trial is the first randomized trial comparing MRI-guided with standard CT-guided SBRT for localized PCa. The primary hypothesis is that MRI-guided SBRT will lead to an improvement in the cumulative incidence of acute grade >= 2 GU toxicity when compared to CT-guided SBRT. The pragmatic superiority design focused on an acute toxicity endpoint will allow an early comparison of the two technologies.
Article
Oncology
Anastasia Chalkidou, Thomas Macmillan, Mariusz T. Grzeda, Janet Peacock, Jennifer Summers, Saskia Eddy, Bola Coker, Hannah Patrick, Helen Powell, Lee Berry, Gareth Webster, Peter Ostler, Peter D. Dickinson, Matthew Q. Hatton, Ann Henry, Stephen Keevil, Maria A. Hawkins, Nick Slevin, Nicholas van As
Summary: Stereotactic ablative body radiotherapy (SABR) shows high overall survival and low toxicity in patients with extracranial oligometastatic cancer, providing evidence for its efficacy in this patient cohort.
Article
Oncology
Francesco Cuccia, Michele Rigo, Vanessa Figlia, Niccolo Giaj-Levra, Rosario Mazzola, Luca Nicosia, Francesco Ricchetti, Giovanna Trapani, Antonio De Simone, Davide Gurrera, Stefania Naccarato, Gianluisa Sicignano, Ruggero Ruggieri, Filippo Alongi
Summary: This study reports the preliminary data of using 1.5T MR-Linacs for prostate or prostate bed re-irradiation. The study found that this treatment option has minimal toxicity and encouraging clinical outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lily Chen, Bhavani S. Gannavarapu, Neil B. Desai, Michael R. Folkert, Michael Dohopolski, Ang Gao, Chul Ahn, Jeffrey Cadeddu, Aditya Bagrodia, Solomon Woldu, Ganesh V. Raj, Claus Roehrborn, Yair Lotan, Robert D. Timmerman, Aurelie Garant, Raquibul Hannan
Summary: This study analyzed the use of stereotactic ablative radiation (SAbR) at a dose of 45 Gy in 5 fractions for prostate cancer. The results showed promising safety profiles, but further prospective studies are needed to establish this dose regimen as standard of care.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Thomas Willigenburg, Joanne M. van der Velden, Cornel Zachiu, Frederik R. Teunissen, Jan J. W. Lagendijk, Bas W. Raaymakers, Johannes C. J. de Boer, Jochem R. N. van der Voort van Zyp
Summary: This study aimed to assess the correlation between the accumulated bladder wall dose and patient-reported urinary toxicity in PCa patients treated with MR-guided SBRT. The results showed that bladder wall dose was correlated with urinary toxicity, making it a promising parameter for predicting patient-reported urinary toxicity.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Medicine, General & Internal
Morgan Michalet, Ons Bettaieb, Samia Khalfi, Asma Ghorbel, Simon Valdenaire, Pierre Debuire, Norbert Ailleres, Roxana Draghici, Mailys De Meric De Bellefon, Marie Charissoux, Pierre Boisselier, Sylvain Demontoy, Alexis Marguerit, Morgane Cabaille, Marie Cantaloube, Aicha Keskes, Touria Bouhafa, Marie-Pierre Farcy-Jacquet, Pascal Fenoglietto, David Azria, Olivier Riou
Summary: Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). This study reviewed data from 12 consecutive patients treated with MRgRT for AGM and assessed the treatment's impact on target volume coverage, organ protection, local control, and overall survival. The results showed improved dosimetric quality and good tolerance of the treatment, with high rates of local control and overall survival. Longer follow-up is needed to evaluate late toxicities and clinical outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Paul V. Nguyen, Bertrand Donneaux, Celine Louis, Zsuzsa Bodgal, Sven Philippi, Sylvie Biver, Berangere Frederick, Ludovic Harze, Yves Lasar, Guillaume Vogin, Philippe Nickers
Summary: Focal SBRT is a feasible and well-tolerated treatment option for low and favorable intermediate-risk prostate cancer, which preserves quality of life.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Jonathan E. Leeman, Kee-Young Shin, Yu-Hui Chen, Raymond H. Mak, Paul L. Nguyen, Anthony V. D'Amico, Neil E. Martin
Summary: In this systematic review and meta-analysis of 29 clinical trials, it was found that MRg-A-SBRT is associated with a significantly reduced risk of acute grade 2 or higher genitourinary and gastrointestinal toxicity compared to CT-SBRT.
Article
Oncology
Amar U. Kishan, Ting Martin Ma, James M. Lamb, Maria Casado, Holly Wilhalme, Daniel A. Low, Ke Sheng, Sahil Sharma, Nicholas G. Nickols, Jonathan Pham, Yingli Yang, Yu Gao, John Neylon, Vincent Basehart, Minsong Cao, Michael L. Steinberg
Summary: MRI-guided SBRT significantly reduces acute grade 2 or greater GU toxic effects and GI toxic effects compared to CT-guided SBRT. This randomized clinical trial provides evidence for the benefits of MRI guidance in prostate cancer treatment. Further follow-up is needed to confirm the long-term effects.
Article
Oncology
Stephen Harrow, David A. Palma, Robert Olson, Stewart Gaede, Alexander V. Louie, Cornelis Haasbeek, Liam Mulroy, Michael Lock, George B. Rodrigues, Brian P. Yaremko, Devin Schellenberg, Belal Ahmad, Sashendra Senthi, Anand Swaminath, Neil Kopek, Mitchell Liu, Roel Schlijper, Glenn S. Bauman, Joanna Laba, X. Melody Qu, Andrew Warner, Suresh Senan
Summary: This study evaluates the effect of ablative therapies in patients with oligometastases over a long-term randomized period. The results indicate that Stereotactic Ablative Radiotherapy (SABR) can significantly improve overall survival and progression-free survival without new major toxicity signals during extended follow-up.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Matthew Van Oirschot, Alanah Bergman, Wilko F. A. R. Verbakel, Lucy Ward, Isabelle Gagne, Vicky Huang, Nick Chng, Peter Houston, Kerry Symes, Christopher G. Thomas, Parminder Basran, David Bowes, Stephen Harrow, Robert Olson, Suresh Senan, Andrew Warner, David A. Palma, Stewart Gaede
Summary: This study assessed the association between target coverage compromise and patient outcomes in SABR treatment for oligometastases. The results showed that for some lesions, a reduction in dose or target coverage was necessary to meet organ at risk constraints. However, target coverage was not significantly associated with survival outcomes or lesional control.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz-Ares, Johan F. Vansteenkiste, Marina C. Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Ozguroglu, Ki H. Lee, Terufumi Kato, Maike de Wit, Takayasu Kurata, Martin Reck, Byoung C. Cho, Suresh Senan, Jarushka Naidoo, Helen Mann, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia
Summary: The study examined the efficacy of consolidation durvalumab in patients with non-small-cell lung cancer, showing significant improvements in overall survival and progression-free survival, with manageable safety. The 5-year follow-up data continued to demonstrate the positive effects of durvalumab on survival and disease progression.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Editorial Material
Oncology
Anand Swaminath, Timothy Ritter, Alexander V. Louie, David A. Palma, Matthias Guckenberger, Suresh Senan, Andrea Bezjak, Drew Moghanaki
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Claire van Vliet, Chris Dickhoff, Idris Bahce, Anton F. Engelsman, Sayed M. S. Hashemi, Cornelis J. A. Haasbeek, Anna M. E. Bruynzeel, Miguel A. Palacios, Annemarie Becker-Commissaris, Berend J. Slotman, Suresh Senan, Famke L. Schneiders
Summary: This study investigated treatment patterns for adrenal metastases using surgery or SABR at a single institution. The number of patients undergoing SABR doubled since 2016, while the numbers undergoing surgery remained unchanged. Both treatments showed low rates of acute toxicity and similar survival outcomes.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
S. Senan, M. Ozguroglu, D. Daniel, A. Villegas, D. Vicente, S. Murakami, R. Hui, C. Faivre-Finn, L. Paz-Ares, Y. L. Wu, H. Mann, P. A. Dennis, S. J. Antonia
Summary: Durvalumab improves progression-free survival and overall survival in patients with or without stage IIIA-N2 non-small-cell lung cancer (NSCLC). Further research is needed to determine the optimal treatment approach for patients who are deemed operable.
Article
Oncology
Florien W. Boele, Patricia W. M. den Otter, Jaap C. Reijneveld, Philip C. de Witt Hamer, Hinke F. van Thuijl, Linda M. C. Lorenz, Pieter Wesseling, Frank J. Lagerwaard, Martin J. B. Taphoorn, Mathilde C. M. Kouwenhoven, Tom J. Snijders, Linda Douw, Martin Klein
Summary: HRQOL and NCF do not appear greatly impacted during long-term survivorship in LGG, but depressive symptoms and fatigue are persistent.
Editorial Material
Oncology
Andrew G. Shuman, Matti S. Aapro, Benjamin Anderson, Katherine Arbour, Pedro C. Barata, Aditya Bardia, Eduardo Bruera, Bruce A. Chabner, Herbert Chen, Edwin Choy, Pierfranco Conte, Giuseppe Curigliano, Don Dizon, Eileen O'Reilly, Antonio Tito Fojo, Hans Gelderblom, Timothy A. Graubert, Jayne S. Gurtler, Evan Hall, Fred R. Hirsch, Ahmed Idbaih, David H. Ilson, Michael Kelley, Carlo La Vecchia, Heinz Ludwig, Beverly Moy, Hyman Muss, Frans Opdam, Rebecca D. Pentz, Marshall R. Posner, Jeffrey S. Ross, Adrian Sacher, Suresh Senan, Enrique Soto Perez de Celis, Kenneth K. Tanabe, Jan B. Vermorken, Eric Wehrenberg-Klee, Susan E. Bates
Summary: In this editorial, the authors discuss the potential implications of the recent Supreme Court decision in Dobbs v. Jackson Women's Health Organization for patients with cancer, in the context of the difficult decision of whether or not to choose pregnancy termination.
Article
Radiology, Nuclear Medicine & Medical Imaging
Koen J. Nelissen, Eva Versteijne, Suresh Senan, Daan Hoffmans, Ben J. Slotman, Wilko F. A. R. Verbakel
Summary: A workflow involving preplanning on diagnostic CT imaging and online plan adaption using cone-beam CT scan was developed for single-visit radiotherapy. The study showed that this workflow can meet clinical goals and outperform initial treatment plans based on daily CT scan.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Moritz Rabe, Miguel A. Palacios, John van Sornsen R. de Koste, Chukwuka Eze, Martin Hillbrand, Claus Belka, Guillaume Landry, Suresh Senan, Christopher Kurz
Summary: This study compared the accumulated doses of MRgRT, non-adaptive IMPT, and online adaptive IMPT for central lung tumors, with a focus on the bronchial tree dose. The results showed that non-adaptive and online adaptive proton therapy achieved significant dose sparing for organs in close proximity to central lung tumors compared to MRgRT. Online adaptive IMPT achieved significantly lower doses to the bronchial tree compared to MRgRT.
Article
Oncology
Koen J. Nelissen, Eva Versteijne, Suresh Senan, Barbara Rijksen, Marjan Admiraal, Jorrit Visser, Sarah Barink, Amy L. de la Fuente, Daan Hoffmans, Ben J. Slotman, Wilko F. A. R. Verbakel
Summary: We developed a rapid palliative radiotherapy workflow using diagnostic imaging for pre-planning and on-couch target and plan adaptation based on a synthetic CT obtained from CBCT. The adapted treatment plans showed significant improvements in target coverage compared to the original plans. Most patients were satisfied with the workflow. The average treatment time, including consultation and on-couch adaptive treatment, was 85 minutes.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Puneeth Iyengar, Sean All, Mark F. Berry, Thomas P. Boike, Lisa Brad fi Eld, Anne -Marie C. Dingemans, Jill Feldman, Daniel R. Gomez, Paul J. Hesketh, Salma K. Jabbour, Melenda Jeter, Mirjana Josipovic, Yolande Lievens, Fiona Mcdonald, Bradford A. Perez, Umberto Ricardi, Enrico Ruffini, Dirk De Ruysscher, Hina Saeed, Bryan J. Schneider, Suresh Senan, Joachim Widder, Matthias Guckenberger
Summary: This guideline aims to review the use of local therapy in the management of extracranial oligometastatic non-small cell lung cancer (NSCLC) and provide recommendations. Currently, data is limited, but with increasing evidence supporting the use of local therapy in NSCLC, this guideline attempts to provide recommendations based on the quality of available data.
PRACTICAL RADIATION ONCOLOGY
(2023)
Article
Oncology
Miguel A. Palacios, Georgi Gerganov, Paul Cobussen, Shyama U. Tetar, Tobias Finazzi, Berend J. Slotman, Suresh Senan, Cornelis J. A. Haasbeek, Iwan Kawrakow
Summary: This study evaluated the accuracy of automatic tumor segmentation in MR-guided radiotherapy (MRgRT) by comparing it to manual delineations performed by experienced observers. The results showed a high level of agreement between automatic segmentation and manual delineation.
PHYSICS & IMAGING IN RADIATION ONCOLOGY
(2023)
Article
Oncology
Hilal Tekatli, Miguel A. Palacios, Famke L. Schneiders, Cornelis J. A. Haasbeek, Ben J. Slotman, Frank J. Lagerwaard, Suresh Senan
Summary: This study investigated the long-term clinical outcomes of MR-guided SF-SABR on a 0.35 T linac for lung tumors. The results showed that SF-SABR, using automatic beam gating during breath-holds, achieved good tumor control and low toxicity.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Famke L. Schneiders, Claire van Vliet, Nicolas Giraud, Anna M. E. Bruynzeel, Ben J. Slotman, Miguel A. Palacios, Suresh Senan
Summary: This study retrospectively reviewed the outcomes of MR-guided adrenal SABR and found that this approach is well tolerated and achieves high local control rates. Further research using deformable dose accumulation is needed to better understand the dose-response relationship.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)